Enalare Therapeutics Receives Additional Funding From BARDA to Further Advance the Development of Agnostic Respiratory Stimulant (ENA-001)
Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today...
Enalare Therapeutics Announces Publication of a Clinical Study Demonstrating the Effect of ENA-001 on Improving Propofol-Induced Depression of the Hypoxic Ventilatory Response
Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today...
Enalare Therapeutics Selected to Present at Three Upcoming Scientific Conferences Regarding Its Lead Compound, ENA-001
Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life- threatening critical care diseases and community health...
Enalare Therapeutics Nominated for Two Citeline Awards in Recognition of Outstanding Clinical Efforts
Enalare Therapeutics Inc., a clinical stage biopharmaceutical
company dedicated to developing novel compounds for the 
treatment of life-threatening critical care diseases and community health emergencies, announced...